#United States #New York #Pomerantz LLP #Nyxoah S.A. #FDA Review

Pomerantz Law Firm Initiates Investigation into Nyxoah S.A.

Pomerantz LLP, a leading law firm, has commenced an investigation on behalf of investors of Nyxoah S.A. (NASDAQ: NYXH), focusing on allegations surrounding potential securities fraud as well as other unlawful business practices linked to the company's operations. The firm is particularly concerned with actions taken by the company's executive officers and directors that might have impacted shareholder interests.

On March 25, 2025, Nyxoah publicly disclosed that the U.S. Food and Drug Administration (FDA) had issued an Approvable Letter regarding the company's Pre-Market Approval (PMA) application for its innovative Genio® system. This development indicated that while the application was on track, it still required further review of manufacturing facilities, methods, and controls before full approval could be granted by the FDA. This news raised concerns among analysts regarding potential delays in the planned commercial launch of the Genio system, casting doubt on the timeline previously anticipated by investors.

The immediate market reaction was significant; Nyxoah's stock price plummeted by $2.42 per share, equivalent to a 21.36% decline, with shares closing at $8.91 on March 26, 2025. This sharp decline following the announcement has triggered alarm among stakeholders, prompting Pomerantz LLP to act swiftly to protect investors' interests.

Investors who believe they have been adversely affected by these developments are encouraged to reach out to Danielle Peyton at Pomerantz LLP for more information about joining a possible class action. This type of collective legal action seeks to recover damages for shareholders who may have experienced financial losses tied to alleged corporate misconduct.

Pomerantz LLP is recognized as a frontrunner in the domains of corporate, securities, and antitrust class litigation. With a history of over 85 years, the firm continues the legacy pioneered by its founder, Abraham L. Pomerantz, who was a prominent figure in establishing the precedent for securities class actions. The firm boasts a strong track record of securing sizable settlements and judgments on behalf of its clients, further underscoring its commitment to holding companies accountable for any violations that infringe upon shareholder rights.

As the investigation unfolds, it is essential for investors to remain vigilant and informed regarding any updates that might arise from both Pomerantz LLP and Nyxoah. Anyone affected by the recent events is urged not to hesitate in seeking guidance and support to ensure their rights are safeguarded. Those interested in the ongoing developments can visit www.pomlaw.com for further insights.

In conclusion, the recent FDA letter regarding the Genio® system has opened a significant chapter in Nyxoah's journey that could have lasting implications for investors. The proactive stance taken by Pomerantz LLP reinforces the importance of corporate accountability and the necessity for investors to seek redress when misrepresentation or other business malpractices come into play. As this situation evolves, the commitment of law firms like Pomerantz underlines the critical blend of legal expertise and advocacy that can help restore investor confidence in the marketplace.